



RECEIVED

SEP 15 2000

Box Seq. GP 1635 \$

WD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 05 2000

5/a

TECH CENTER 1600/2900

MJD

GROUP: 1635
EXAMINER: Epps, J.APPLICANT: Agrawal
SERIAL NO.: 09/412,947
DOCKET NO.: HYZ-050CP2
FILING DATE: October 5, 1999
TITLE: MODIFIED PROTEIN KINASE A-SPECIFIC
OLIGONUCLEOTIDES AND METHODS OF THEIR USE

RECEIVED

SEP 06 2000

RECEIVED
SEP 12 2000
TECH CENTER 1600/2900
TC 2700 MAIL ROOM

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231TRANSMITTAL LETTER

Dear Sir:


Enclosed herewith for filing in the above referenced patent application are the following documents:

1. Response to Office Action;
2. Statement Under 37 C.F.R. §1.82(f);
3. Written copy of Sequence Listing Information;
4. Diskette containing Sequence Listing information;
5. Copy of Notice to Comply with Sequence Listing Requirement; and
6. Return Postcard.

RECEIVED
SEP 11 2000
TC 1100 MAIL ROOM

Respectfully submitted,

HALE AND DORR LLP



Ann-Louise Kerner, Ph.D.

Registration No. 33,523

Attorney for Applicants


August 24, 2000
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (fax)

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

Date: August 24, 2000

By: 
Tae H. Kim



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/412,947 10/05/99 AGRAWAL

5 HYZ-050CP2

EXAMINER

HM22/0424

ANN LOUISE KERNER PHD
HALE AND DORR LLP
60 STATE STREET
BOSTON MA 02109

EPPS, J

ART UNIT

PAPER NUMBER

1635

DATE MAILED:

RECEIVED
SEP 12 2000
TC 2700 MAIL ROOM

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

HALE & DORR DOCKETING

Action OA (Seq.) on 24 Apr 00

Docket Date 24 May 00


Docket By LD

On 26 Apr 00

RECEIVED
SEP 11 2000
15 1100 MAIL ROOM

Application/Control Number: 09/412,947

Art Unit: 1635



Page 2

RECEIVED

SEP 06 2000

TECH CENTER 1600/2500

1C 2100 MAIL ROOM

SEP 12 2000

RECEIVED

DETAILED ACTION

Sequence Information

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. The applicant did not submit a CRF with this application.

2. Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

1C 2100 MAIL ROOM

SEP 14 2000

RECEIVED



Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps whose telephone number is (703) 308-8883. The examiner can normally be reached on Monday through Friday from 8:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, George Elliott, can be reached at (703) 308-4003. The fax number for this group is (703) 305-7939.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Janet L. Epps, Ph.D.

April 20, 2000

Remy Yucel
REMY YUCEL, PH.D.
PATENT EXAMINER

RECEIVED
SEP 12 2000
TC 2700 MAIL ROOM

RECEIVED
SEP 11 2000
TC 1700 MAIL ROOM

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure, on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE